I have mixed connective tissue disease with a speckled ANA, high anti‑U1 RNP titres, modest creatine kinase elevation, normal electromyography, G6PD deficiency, and pericarditis—what treatment and monitoring plan should I follow?

You're Not Fucked—But You Need Aggressive, Coordinated Care Right Now

With mixed connective tissue disease (MCTD) presenting with pericarditis, elevated CK, and high anti-U1 RNP antibodies, you require immediate corticosteroid therapy combined with close cardiac monitoring and rheumatology follow-up, with your G6PD deficiency requiring careful medication selection to avoid hemolytic triggers.

Immediate Treatment Priorities

Pericarditis Management

Your pericarditis is the most urgent concern requiring immediate attention:

• Start high-dose NSAIDs (ibuprofen 600-800mg three times daily OR indomethacin 25-50mg three times daily) as first-line therapy
• Critical caveat with G6PD deficiency: Avoid aspirin entirely—it can trigger hemolysis. Ibuprofen and indomethacin are generally safer options, but monitor closely
• Add colchicine 0.5-0.6mg twice daily (or once daily if <70kg) for at least 3 months to prevent recurrence
• Corticosteroids (prednisone 0.5mg/kg/day) should be added if NSAIDs are contraindicated or if pericarditis is severe 1

Myositis Component

Your modest CK elevation with normal EMG suggests mild muscle involvement (Grade 1):

• Continue monitoring without immediate corticosteroids if you have no muscle weakness 2
• If you develop muscle weakness: Start prednisone 0.5mg/kg/day 2
• Monitor CK levels every 2-4 weeks initially—if CK rises to ≥3× upper limit of normal, escalate to prednisone 0.5-1mg/kg/day 3
• Check troponin to rule out myocardial involvement, which would require more aggressive therapy 2

Comprehensive MCTD Treatment Strategy

First-Line Immunosuppression

Based on your MCTD diagnosis with multiple organ involvement:

Hydroxychloroquine 400mg daily is foundational therapy—it's safe with G6PD deficiency at standard doses and provides disease-modifying effects 4

Add mycophenolate mofetil 1000-1500mg twice daily as steroid-sparing agent if:

• Pericarditis recurs despite initial therapy
• CK continues rising
• New organ involvement develops 5, 6

G6PD-Specific Medication Precautions

Absolutely avoid:

• Aspirin (high hemolysis risk)
• Sulfonamides
• Nitrofurantoin
• Primaquine
• Rasburicase

Use with caution (monitor hemoglobin):

• High-dose vitamin C
• Certain antibiotics (quinolones, chloramphenicol)

Generally safe:

• Corticosteroids
• Hydroxychloroquine (standard doses)
• Mycophenolate
• Azathioprine
• NSAIDs (except aspirin)

Essential Monitoring Protocol

Cardiac Surveillance

Given pericarditis and potential cardiac involvement in MCTD:

• Echocardiogram at baseline and repeat in 2-4 weeks to assess for effusion progression or tamponade 1
• ECG to monitor for arrhythmias or conduction abnormalities
• Troponin to detect myocardial involvement 2
• If pericardial effusion develops: Consider pericardiocentesis if hemodynamically significant 1

Laboratory Monitoring Schedule

Every 2-4 weeks initially:

• CK and aldolase (muscle inflammation)
• CBC with differential (G6PD-related hemolysis, medication toxicity)
• Comprehensive metabolic panel
• ESR and CRP (disease activity)

Every 3 months:

• Anti-U1 RNP titers (trend, not absolute values)
• Urinalysis (renal involvement screening)
• Liver function tests (medication monitoring)

Every 6-12 months:

• Pulmonary function tests (MCTD can cause ILD)
• High-resolution chest CT if PFTs decline or respiratory symptoms develop 5, 7

When to Escalate Therapy

Red Flags Requiring Urgent Rheumatology Consultation

Escalate immediately if:

• CK rises to ≥3× upper limit normal with muscle weakness (Grade 2 myositis) 2
• Pericardial effusion with tamponade physiology 1
• New dysphagia or respiratory muscle weakness
• Fever with worsening symptoms
• Hemolytic anemia (hemoglobin drop with elevated bilirubin/LDH)

Second-Line Therapies

If inadequate response after 4-6 weeks on initial therapy:

Add rituximab 1000mg IV × 2 doses (2 weeks apart) for:

• Refractory myositis 6
• Progressive disease despite mycophenolate
• Severe organ involvement

Consider IVIG 2g/kg divided over 2-5 days for:

• Severe myositis with dysphagia or respiratory involvement 6
• Contraindication to other immunosuppressants

Methotrexate 15-25mg weekly is alternative if mycophenolate not tolerated 8

Prognosis Reality Check

You're actually in a manageable situation:

• Normal EMG is reassuring—no significant nerve/muscle damage yet
• Pericarditis in MCTD typically responds well to treatment 1
• Early recognition allows intervention before irreversible organ damage
• MCTD generally has better prognosis than individual CTDs when properly treated 9

The key is aggressive early treatment and close monitoring—patients who receive prompt, appropriate therapy typically achieve good disease control and maintain quality of life 4, 10.

Practical Next Steps

1. This week: Start NSAIDs + colchicine for pericarditis (avoid aspirin), get baseline echocardiogram and troponin
2. Within 2 weeks: Establish care with rheumatologist experienced in MCTD, repeat CK and cardiac monitoring
3. Within 1 month: Initiate hydroxychloroquine, consider mycophenolate if disease activity persists
4. Ongoing: Strict medication avoidance list for G6PD, regular monitoring per schedule above

The bottom line: MCTD with your presentation is serious but highly treatable. The combination of pericarditis and myositis requires immediate attention, but with appropriate therapy and monitoring, most patients achieve remission or low disease activity. Your G6PD deficiency adds complexity but doesn't fundamentally change the treatment approach—just requires careful medication selection.